Abstract:Background Patients with obesity experience an increased duration of labor with increased risk of perinatal morbidity. Compared to parturients without obesity, they also experience fewer uterine contractions after administration of misoprostol. It is unclear whether the same dose of misoprostol should be used for induction of labor in patients with obesity compared to non-obese patients. Therefore, we sought to investigate if a higher dose of misoprostol for patients with obesity is more effective. Objective To determine if 50mcg compared to 25mcg of vaginal misoprostol reduces the time from induction start to delivery in patients with obesity. Study Design We performed a double-blinded, pragmatic randomized controlled trial, between June 1, 2022, and July 17, 2023. Patients with a body mass index (BMI) ≥ 30 kg/m 2 undergoing labor induction ≥ 36 weeks, singleton gestations, and a cervical dilation ≤ 3cm on admission, were included. Patients were excluded if they had a contraindication to vaginal delivery or misoprostol administration. Patients were randomized to 25 or 50 mcg of vaginal misoprostol, stratified by parity, BMI < 40 kg/m 2 or ≥ 40 kg/m 2 , and provider intent to use mechanical dilation at the onset of labor induction. Usual labor management was followed at the discretion of the provider. The primary outcome was time from induction to delivery. A priori, we estimated 90 subjects per group (N=180) were needed for an 85% power to detect a 3-hour difference between groups with a type I error of 5%. Analysis was intention-to-treat. A two-sample t-test was used for the primary outcome, Cohen's d as a measure of effect, and P values were reported. Results Of the 180 patients randomized, 88 were assigned to the 25mcg group and 92 were assigned to the 50mcg group. 96.1% of patients received the designated intervention. Baseline characteristics were similar between groups. No difference was found in the primary outcome of time to delivery (21.6 hours vs. 18.6 hours; d = 0.28; 95% confidence interval, -0.02-0.57). In a planned subgroup analysis, multiparous patients delivered faster in the 50mcg group (15.2 hours vs. 12.0 hours; d = 0.51; 95% confidence interval, 0.04-0.97). The risk of tachysystole associated with fetal heart tracing changes was rare overall (2.2%) and not significantly different between groups. No differences in maternal or neonatal adverse effects were observed. Conclusion Patients with obesity undergoing cervical ripening with 50mcg of vaginal misoprostol experienced similar time to delivery when compared to 25mcg. However, multiparous patients had a significantly reduced time to delivery when 50mcg was used. A higher dose of misoprostol may be a promising intervention for reducing time in labor which warrants further study.

A Randomized Study of Two Doses of Misoprostol in Combination with Mifepristone for Inducted Labor in Second-trimester Pregnancy

The Retrospective Analysis on the Influence of Taking Mifepristone and Misoprostol During First-trimester Pregnancy and Its Following Impact on Tissue Residual After Induced Abortion

Preliminary study on the effect of mifepristone followed by diffferent regimens of misoprostol for termination of pregnancy between 8 and 16 weeks of gestation

Analysis of Mifeprestone Combine Misoprostol Induced Early Pregnancy Ending after Cesarean Section

Misoprostol versus prostaglandin E2 gel for labor induction in premature rupture of membranes after 34 weeks of pregnancy

The second trimester termination with combination of mifepristone and misoprostol:A randomized comparison with dry and sodium chloride solution-moistened misoprostol tablets administered intravaginally

Comparison of two labor induction regimens with intravaginal misoprostol 25 μg and adverse perinatal outcomes

Optimal Misoprostol Dosing Among Patients with a BMI Greater Than 30: A Randomized Controlled Trial

Misoprostol in Labour Induction of Term Pregnancy:A Meta-Analysis

A Comparison of the Efficacy and Safety of Mifepristone and Misoprostol Versus Misoprostol alone for Induction of Labour in Nigerian Women with Intrauterine Fetal Death: A Triple Blind Randomized Controlled Trial

Comparison of Misoprostol for Labor Induction: Vaginal Insert Versus Oral Application Concerning Efficiency and Safety

Comparison of mifepristone plus misoprostol with misoprostol alone for first trimester medical abortion: A systematic review and meta-analysis

The Efficacy and Influence Factors Analysis of Mifepristone Combined with Estrogen-Progesterone in the Treatment of Incomplete Abortion

Impaction of Induced Labour using Mifepristone on Genetic Stability of Pregnant Women

Comparison of the Sublingual and Vaginal Misoprostol for Medical Termination of Pregnancy in Cases of First and Second Trimester Abortion: A Quasi Experimental Study

Efficacy and Safety of Mifepristone and Misoprostol Compared to Misoprostol Alone for the Resolution of Miscarriage and Intrauterine Fetal Death: A Systematic Review and Meta-Analysis

Mifepristone and misoprostol versus misoprostol alone for induction of labor in women with intrauterine fetal death: A meta‐analysis and systematic review

Medical treatment of miscarriage using misoprostol-a retrospective study

A Randomized Controlled Trial Comparing the Management of Incomplete Abortion with Oral 600 mg Misoprostol with Manual Vacuum Aspiration (MVA)

Low-Dose Oral Misoprostol Versus Oxytocin Infusion For Induction Of Labor In Pregnant Women With Term Premature Rupture Of Membranes in China: A retrospective Nested Case-Control Study

Study on the Effects of Mifepristone and Misoprostol to Terminate the Medium-Term Pregnancy